• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Vapotherm Inc.

    9/20/24 10:23:54 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    S-8 POS 1 vapo20240916e_s8pos.htm FORM S-8 POS vapo20240916e_s8pos.htm

    As filed with the Securities and Exchange Commission on September 20, 2024

    Registration No. 333-229327

    Registration No. 333-236953

    Registration No. 333-253597

    Registration No. 333-262989

    Registration No. 333-270001

    Registration No. 333-277422

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM S-8

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-229327

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-236953

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-253597

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-262989

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270001

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-277422

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     


     
    vapotherm01.jpg

    VAPOTHERM, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    (State or other jurisdiction of incorporation or organization)

    46-2259298

    (I.R.S. Employer Identification No.)

       

    100 Domain Drive,

    Exeter, New Hampshire

    (Address of Principal Executive Offices)

    03833

    (Zip Code)

     


     

    Vapotherm, Inc. 2005 Stock Incentive Plan, as amended

    Vapotherm, Inc. 2015 Stock Incentive Plan

    Vapotherm, Inc. 2018 Employee Stock Purchase Plan

    Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan

    (Full title of the plan)

     

    James A. Lightman

    Senior Vice President and General Counsel

    Vapotherm, Inc.

    100 Domain Drive

    Exeter, NH 03833

    (Name and address of agent for service)

     

    (603) 658-0011

    (Telephone number, including area code, of agent for service)

     

     

     

     

    Copies requested to:

    Amy E. Culbert, Esq.

    Fox Rothschild LLP

    City Center

    33 South Sixth Street, Suite 3600

    Minneapolis, Minnesota 55402-3601

    (612) 607-7000

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
        Emerging growth company ☐

                                                                   

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    DEREGISTRATION OF UNSOLD SECURITIES

    This Post-Effective Amendment relates to the deregistration of all shares of common stock, par value $0.001 per share (the “Common Stock”), of Vapotherm, Inc. (the “Registrant”) remaining unsold or otherwise unissued under the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by the Registrant with the Securities and Exchange Commission (the “SEC”):

     

     

    1.

    Registration Statement on Form S-8 (Reg. No. 333-229327) filed with the SEC on January 22, 2019 pertaining to the registration of (i) 20,210 shares of Common Stock available for issuance under the Vapotherm, Inc. 2005 Stock Incentive Plan, as amended, (ii) 75,414 shares of Common Stock available for issuance under the Vapotherm, Inc. 2015 Stock Incentive Plan, (iii) 42,490 shares of Common Stock available for issuance under the Vapotherm, Inc. 2018 Employee Stock Purchase Plan (the “ESPP”) and (iv) 211,573 shares of Common Stock available for issuance under the Vapotherm, Inc. 2018 Equity Incentive Plan (as amended and restated, the “2018 Plan”);

     

     

    2.

    Registration Statement on Form S-8 (Reg. No. 333-236953) filed with the SEC on March 6, 2020 pertaining to the registration of (i) 26,064 additional shares of Common Stock available for issuance under the ESPP and (ii) 104,257 additional shares of Common Stock available for issuance under the 2018 Plan;

     

     

    3.

    Registration Statement on Form S-8 (Reg. No. 333-253597) filed with the SEC on February 26, 2021 pertaining to the registration of (i) 32,284 additional shares of Common Stock available for issuance under the ESPP and (ii) 129,137 additional shares of Common Stock available for issuance under the 2018 Plan;

     

     

    4.

    Registration Statement on Form S-8 (Reg. No. 333-262989) filed with the SEC on February 24, 2022 pertaining to the registration of (i) 32,657 additional shares of Common Stock available for issuance under the ESPP and (ii) 130,631 additional shares of Common Stock available for issuance under the 2018 Plan;

     

     

    5.

    Registration Statement on Form S-8 (Reg. No. 333-270001) filed with the SEC on February 24, 2023 pertaining to the registration of (i) 35,580 additional shares of Common Stock available for issuance under the ESPP and (ii) 142,323 additional shares of Common Stock available for issuance under the 2018 Plan; and

     

     

    6.

    Registration Statement on Form S-8 (Reg. No. 333-277422) filed with the SEC on February 27, 2024 pertaining to the registration of (i) 61,658 additional shares of Common Stock available for issuance under the ESPP and (ii) 656,632 additional shares of Common Stock available for issuance under the 2018 Plan.

     

    All shares have been adjusted to reflect the one-for-eight reverse stock split effective August 18, 2023.

     

    On September 20, 2024, pursuant to the Agreement and Plan of Merger dated as of June 17, 2024 (the “Merger Agreement”) among Veronica Holdings, LLC, a Delaware limited liability company (“Topco”), Veronica Intermediate Holdings, LLC, a Delaware limited liability company and wholly owned subsidiary of Topco (“Parent”), Veronica Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and the Registrant, Merger Sub merged with and into the Registrant (the “Merger”), and as a result of the Merger, the separate corporate existence of Merger Sub ceased, and the Registrant continued as the surviving corporation of the Merger and as a wholly owned subsidiary of Parent.

     

    As a result of the Merger and the related transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings of the Registrant’s securities pursuant to the Registration Statements. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all such securities of the Registrant registered but unsold or otherwise unissued under the Registration Statements, if any, as of the date hereof.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Exeter, State of New Hampshire, on September 20, 2024.

     

     

    VAPOTHERM, INC. 

     

     

     

     

     

     

     

     

     

     

    By:

    /s/ Joseph Army

     

     

     

    Joseph Army 

     

     

     

    President and Chief Executive Officer 

     

     

     

     

     

     

    No other person is required to sign this Post-Effective Amendment to the Registration Statements on Form S-8 in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

     
    Get the next $VAPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vapotherm downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

      5/6/22 7:28:09 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

      4/7/22 7:25:32 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Piper Sandler reiterated coverage on Vapotherm with a new price target

      Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

      2/25/21 7:36:13 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vapotherm Announces Closing of Merger

      EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

      9/20/24 10:33:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports Second Quarter 2024 Financial Results

      EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

      8/12/24 5:15:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

      EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

      6/17/24 6:55:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

      TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

      9/8/23 8:30:00 AM ET
      $IART
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 5:01:08 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:43:19 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:14:26 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VAPO
    SEC Filings

    See more

    $VAPO
    Financials

    Live finance-specific insights

    See more
    • Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

      4/A - VAPOTHERM INC (0001253176) (Issuer)

      10/4/23 4:11:34 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form 15-12G filed by Vapotherm Inc.

      15-12G - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 11:32:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:03 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:04 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm To Report Second Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

      7/25/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

      5/3/23 4:10:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm To Report First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

      4/27/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/24/24 7:04:57 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/20/24 10:32:59 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vapotherm Inc.

      SC 13G - VAPOTHERM INC (0001253176) (Subject)

      7/18/24 7:24:17 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care